Please select the option that best describes you:

How would you approach a patient who has developed neutropenia with the combination of trastuzumab/pertuzumab in the adjuvant setting?   

Would you consider the discontinuation of either anti-HER2 agent or both?



Answer from: Medical Oncologist at Community Practice
Sign in or Register to read more